Critical Contrast: Mirum Pharmaceuticals (NASDAQ:MIRM) versus Evogene (NASDAQ:EVGN)

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and Evogene (NASDAQ:EVGN – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Valuation & Earnings

This table compares Mirum Pharmaceuticals and Evogene”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mirum Pharmaceuticals $670.78 million 9.15 -$23.36 million ($15.47) -6.08
Evogene $3.85 million 0.84 -$8.48 million ($0.91) -0.41

Evogene has lower revenue, but higher earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Mirum Pharmaceuticals has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Evogene has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Insider & Institutional Ownership

10.4% of Evogene shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Mirum Pharmaceuticals and Evogene, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirum Pharmaceuticals 1 0 13 1 2.93
Evogene 1 0 0 0 1.00

Mirum Pharmaceuticals currently has a consensus price target of $155.56, suggesting a potential upside of 65.51%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Mirum Pharmaceuticals is more favorable than Evogene.

Profitability

This table compares Mirum Pharmaceuticals and Evogene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mirum Pharmaceuticals -134.75% -97.25% -12.59%
Evogene -694.18% -156.53% -86.80%

Summary

Mirum Pharmaceuticals beats Evogene on 10 of the 15 factors compared between the two stocks.

About Mirum Pharmaceuticals

(Get Free Report)

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.

About Evogene

(Get Free Report)

Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms. Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis.

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.